| scholarly article | Q13442814 |
| P50 | author | Sara Brucker | Q63345510 |
| Peter A. Fasching | Q64005064 | ||
| Peyman Hadji | Q112631966 | ||
| Andreas Schneeweiss | Q37074948 | ||
| Michael P. Lux | Q37372079 | ||
| P2093 | author name string | Michael P Lux | |
| Peter A Fasching | |||
| Volkmar Müller | |||
| Johannes Ettl | |||
| Achim Wöckel | |||
| Andreas Schneeweiss | |||
| Hans Tesch | |||
| Wolfgang Janni | |||
| Diana Lüftner | |||
| Andreas D Hartkopf | |||
| Manfred Welslau | |||
| Tanja N Fehm | |||
| Florin-Andrei Taran | |||
| Florian Schütz | |||
| Erik Belleville | |||
| Friedrich Overkamp | |||
| Hans-Christian Kolberg | |||
| Naiba Nabieva | |||
| P2860 | cites work | Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial | Q47963228 |
| Efficacy of PI3K/AKT/mTOR pathway inhibitors for the treatment of advanced solid cancers: A literature-based meta-analysis of 46 randomised control trials. | Q48097821 | ||
| HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures | Q48134701 | ||
| Filtration based assessment of CTCs and CellSearch® based assessment are both powerful predictors of prognosis for metastatic breast cancer patients. | Q49796329 | ||
| Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry. | Q50866974 | ||
| Update Breast Cancer 2018 (Part 2) - Advanced Breast Cancer, Quality of Life and Prevention. | Q52632715 | ||
| Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. | Q52675952 | ||
| Biomarkers of DNA Repair and Related Pathways: Significance of Treatment in Triple-Negative Breast Cancer. | Q52767437 | ||
| Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer. | Q53012804 | ||
| Risk, Prediction and Prevention of Hereditary Breast Cancer - Large-Scale Genomic Studies in Times of Big and Smart Data. | Q54950358 | ||
| Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer etc. | Q56967384 | ||
| BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study | Q56968709 | ||
| The liquid biopsy in the management of colorectal cancer patients: Current applications and future scenarios | Q57175454 | ||
| BRCA mutations and their influence on pathological complete response and prognosis in a clinical cohort of neoadjuvantly treated breast cancer patients | Q57990746 | ||
| Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial | Q59565062 | ||
| Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial | Q61249036 | ||
| Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3 | Q88963509 | ||
| Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 | ||
| Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer | Q27851691 | ||
| Trastuzumab emtansine for HER2-positive advanced breast cancer | Q27851917 | ||
| Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer | Q27853134 | ||
| Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers | Q28069910 | ||
| Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer | Q29417100 | ||
| Detection of circulating tumor DNA in early- and late-stage human malignancies | Q29615778 | ||
| Circulating tumor cells, disease progression, and survival in metastatic breast cancer | Q29619276 | ||
| Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer | Q29620676 | ||
| Computerized patient identification for the EMBRACA clinical trial using real-time data from the PRAEGNANT network for metastatic breast cancer patients | Q31107007 | ||
| Cell-free nucleic acids as biomarkers in cancer patients | Q34184393 | ||
| Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer | Q34996647 | ||
| Biomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study Network | Q35054455 | ||
| 19p13.1 is a triple-negative-specific breast cancer susceptibility locus | Q35871567 | ||
| Common breast cancer susceptibility loci are associated with triple-negative breast cancer | Q35891162 | ||
| Circulating tumor cells (CTC) detection: clinical impact and future directions. | Q36741696 | ||
| Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study | Q36924426 | ||
| Health-related Quality of Life in Metastatic and Adjuvant Breast Cancer Patients | Q37341647 | ||
| Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial | Q38373098 | ||
| MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. | Q38376037 | ||
| Implementation and Feasibility of Electronic Patient-Reported Outcome (ePRO) Data Entry in the PRAEGNANT Real-Time Advanced and Metastatic Breast Cancer Registry | Q38606464 | ||
| Electronic-Based Patient-Reported Outcomes: Willingness, Needs, and Barriers in Adjuvant and Metastatic Breast Cancer Patients. | Q38636290 | ||
| Treating cancer with selective CDK4/6 inhibitors | Q38794109 | ||
| The PI3K Pathway: Background and Treatment Approaches | Q39147158 | ||
| Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation | Q39348799 | ||
| Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer | Q40142509 | ||
| Predicting Triple-Negative Breast Cancer Subtype Using Multiple Single Nucleotide Polymorphisms for Breast Cancer Risk and Several Variable Selection Methods | Q41011976 | ||
| Reliability of an e-PRO Tool of EORTC QLQ-C30 for Measurement of Health-Related Quality of Life in Patients With Breast Cancer: Prospective Randomized Trial. | Q42236299 | ||
| Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy | Q43222794 | ||
| Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment | Q45060789 | ||
| Circulating Tumour Cells, Circulating Tumour DNA and Circulating MicroRNA in Metastatic Breast Carcinoma - What is the Role of Liquid Biopsy in Breast Cancer? | Q47150180 | ||
| Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer. | Q47185834 | ||
| Homologous Recombination Deficiency and Platinum-Based Therapy Outcomes in Advanced Breast Cancer | Q47562675 | ||
| PI3K/mTOR Inhibitors in the Treatment of Luminal Breast Cancer. Why, When and to Whom? | Q47578323 | ||
| Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry | Q47663023 | ||
| P433 | issue | 11 | |
| P921 | main subject | genomics | Q222046 |
| gynaecology | Q1221899 | ||
| immunotherapy | Q1427096 | ||
| obstetrics | Q5284418 | ||
| P304 | page(s) | 1119-1128 | |
| P577 | publication date | 2018-11-01 | |
| P1433 | published in | Geburtshilfe und Frauenheilkunde: Ergebnisse der Forschung für die Praxis | Q26841999 |
| P1476 | title | Update Breast Cancer 2018 (Part 4) - Genomics, Individualized Medicine and Immune Therapies - in the Middle of a New Era: Treatment Strategies for Advanced Breast Cancer | |
| P478 | volume | 78 |
| Q64102991 | Update Breast Cancer 2019 Part 2 – Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice | cites work | P2860 |
Search more.